What question did this study set out to answer?

The study aims to evaluate the influence of finerenone on uric acid levels and renal function in hyperuricemic patients with diabetic kidney disease.

March 5, 2026Open Access

Finerenone is associated with pronounced uric acid reduction in hyperuricemic diabetic kidney disease: a real-world analysis

Key Points

The study aims to evaluate the influence of finerenone on uric acid levels and renal function in hyperuricemic patients with diabetic kidney disease.
Retrospective analysis of 124 patients with type 2 diabetic kidney disease.
Assessment of uric acid, albuminuria, and eGFR changes before and after finerenone treatment.
Exclusion of patients with recent gout or urate-lowering therapy.
Statistical analyses conducted using linear mixed models and multivariable regression.
Finerenone significantly reduced uric acid levels by an adjusted mean difference of −47.9 μmol/L.
The reduction was more pronounced in patients with baseline hyperuricemia (−88.6 μmol/L).
Albuminuria decreased by 39.4%.
eGFR declined slightly by −2.7 mL/min/1.73 m².
The SUA reduction was independent of other treatments.

Abstract

Background Diabetic kidney disease (DKD) is a critical complication of type 2 diabetes, often compounded by hyperuricemia, which may accelerate renal function decline. While finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), provides renal and cardiovascular benefits, its impact on uric acid (UA) metabolism in real-world DKD patients, particularly those with high baseline SUA, remains controversial. Methods In this retrospective, single-center study, we included 124 patients with type 2 DKD (baseline eGFR ≥60 mL/min/1.73 m 2 ) who initiated finerenone. Patients with recent gout or urate-lowering therapy were excluded. Changes in SUA, urinary albumin-to-creatinine ratio (UACR), and eGFR were assessed before and after 1–3 months of treatment. Statistical analyses employed linear mixed models for longitudinal data and multivariable regression. Results Linear mixed model analysis showed finerenone treatment was associated with a significant reduction in SUA (adjusted mean difference: −47.9 μmol/L, 95% CI: −63.5 to −32.3; p 0.001). This reduction was substantially greater in patients with baseline hyperuricemia (−88.6 μmol/L) than in those without (−16.6 μmol/L; p for interaction = 0.003). UACR decreased by 39.4% (p 0.001), while eGFR showed a small but significant decline (−2.7 mL/min/1.73 m 2 , p = 0.019). The SUA-lowering association was independent of concomitant SGLT2 inhibitor or GLP-1 receptor agonist use in multivariable analyses. Hyperkalemia (potassium ≥5.5 mmol/L) occurred in 0.8% of patients. Conclusion In this real-world cohort, finerenone use was associated with significant reductions in albuminuria and SUA, particularly among patients with hyperuricemia. These findings suggest a potential dual benefit in this high-risk subgroup and highlight the importance of baseline SUA in interpreting finerenone’s metabolic effects. The observed SUA reduction warrants further prospective investigation.

Ask AI

Mark Helpful

Bookmark

Relay

View Full Paper